Hoth Therapeutics rises as AI used to speed rare cancer drug development

Shares of Hoth Therapeutics HOTH.O rise 4.33% to $1.04 premarket

Co says it is using OpenAI tools to help develop drug for rare cancers caused by faulty KIT gene, which can drive tumor growth

Co says early tests of its experimental drug, HT-KIT, sharply lowered KIT gene levels in lab and animal studies, with no serious side effects

 HOTH's HT-KIT also led to tumor shrinkage in animals within just over a week, co says

 Co preparing to seek U.S. approval to begin human testing; drug has orphan status

Shares up ~32% in 2025